GlassScriptPhysician profile
Margery A Kates
NPI 1063413987
$3,530.76
in general payments reported to CMS, 2019-2025
30 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $606 · 2021: $616 · 2022: $566 · 2023: $685 · 2024: $443 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.97 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $627.58 | 2019-2023 | |
| Astellas Pharma US INC | $420.33 | 2022-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $271.80 | 2019-2025 | |
| Therapeuticsmd, INC. | $255.51 | 2019-2022 | |
| Exeltis, USA INC. | $240.45 | 2019-2024 | Slynd, Solosec |
| Pfizer INC. | $235.11 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $217.00 | 2022-2025 | |
| Coopersurgical, INC. | $150.34 | 2019-2023 | Paragard T 380a, Mara Console |
| Merck Sharp & Dohme LLC | $130.31 | 2019-2023 | Gardasil 9 |
| Amgen INC. | $124.57 | 2020-2024 | Evenity, Prolia |
| Aspira Women'S Health INC | $122.76 | 2021-2022 | |
| Evofem Biosciences, INC. | $118.76 | 2020-2025 | Solosec, Phexx, Phexxi |
| Lupin INC. | $73.00 | 2019-2020 | |
| Allergan, INC. | $59.26 | 2019 | |
| Hologic Sales and Service, LLC | $56.44 | 2019-2023 | Coolseal Generator, Novasure |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $55.68 | 2019-2024 | Intrarosa, Femring |
| Amag Pharmaceuticals, INC. | $45.91 | 2019-2020 | |
| Avion Pharmaceuticals | $42.50 | 2019-2021 | |
| Organon LLC | $40.76 | 2021-2022 | |
| Shield Therapeutics INC | $39.90 | 2024-2025 | |
| Scynexis, INC. | $28.07 | 2021 | |
| Mylan Pharmaceuticals INC. | $26.90 | 2021 | |
| Myovant Sciences INC. | $24.18 | 2022 | |
| Duchesnay USA Incorporated | $22.08 | 2020 | |
| Roche Diagnostics Corporation | $20.36 | 2019 | |
| Medtronic, INC. | $19.76 | 2024 | Ligasure |
| Sage Therapeutics, LLC | $18.45 | 2024 | |
| Mycovia Pharmaceuticals, INC. | $15.74 | 2023 | Vivjoa |
| Agile Therapeutics, INC. | $14.44 | 2021 | |
| Minerva Surgical, INC | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margery Kates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.